Furthermore, although several drugs aimed at inhibiting the MAPK/ERK pathway have progressed to the preclinical research stage and demonstrate potential for treating RA, these drugs frequently fail to achieve precise inhibition of this signaling pathway. The gene discussed is MAPK1; the disease is rheumatoid arthritis.